Home > Boards > US Listed > Biotechs > Seattle Genetics (SGEN)

*****Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TREND1 Member Profile
Member Level 
Followed By 409
Posts 55,045
Boards Moderated 15
Alias Born 12/16/01
160x600 placeholder
Seagen recommends rejection of 'mini-tender' offer from TRC capital Seeking Alpha - 3/5/2021 9:29:29 AM
Seagen Recommends Rejection Of 'Mini-Tender' Offer from TRC Capital Investment Corporation Business Wire - 3/5/2021 8:00:00 AM
Seagen to Present at the Cowen 41st Annual Healthcare Conference Business Wire - 2/24/2021 8:00:00 AM
Astellas and Seagen submit two approval requests for bladder cancer therapy Seeking Alpha - 2/18/2021 4:12:28 PM
Seagen & Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfort... Business Wire - 2/18/2021 8:00:00 AM
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfo... PR Newswire (US) - 2/18/2021 8:00:00 AM
Schedule 13g Edgar (US Regulatory) - 2/16/2021 4:23:42 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 12:31:14 PM
Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in ... PR Newswire (US) - 2/12/2021 2:15:00 PM
Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with P... PR Newswire (US) - 2/12/2021 2:15:00 PM
Seagen & Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Pa... Business Wire - 2/12/2021 2:15:00 PM
Seagen & Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Pre... Business Wire - 2/12/2021 2:15:00 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/12/2021 7:53:17 AM
Seagen’s Tukysa wins European approval for breast cancer Seeking Alpha - 2/12/2021 7:45:48 AM
European Commission Approves Seagen’s TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastati... Business Wire - 2/12/2021 6:45:00 AM
European Commission Approves Seagen’s TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastati... Business Wire - 2/12/2021 6:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/11/2021 4:08:15 PM
Seattle Genetics EPS beats by $0.04, beats on revenue Seeking Alpha - 2/11/2021 4:06:40 PM
Seagen Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire - 2/11/2021 4:02:00 PM
Seagen Q4 2020 Earnings Preview Seeking Alpha - 2/10/2021 5:35:10 PM
Genmab and Seagen submit tisotumab vedotin BLA to the FDA Seeking Alpha - 2/10/2021 4:26:56 PM
Seagen & Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metasta... Business Wire - 2/10/2021 4:05:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/10/2021 11:58:40 AM
Ocugen, CRH Medical leads healthcare gainers; ERYTECH Pharma, Panbela Therapeutics among major losers Seeking Alpha - 2/8/2021 11:01:06 AM
TREND1 Member Level  Saturday, 07/16/16 03:28:06 PM
Re: None
Post # of 271 
*****Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2016 financial results on Tuesday, July 26 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Tuesday, July 26, 2016

1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
• Telephone 888-576-4398 (domestic) or 719-325-2329 (international); conference ID 2574870
• Webcast available at www.seattlegenetics.com in the Investors and News section

REPLAY access
• Telephone replay will be available beginning at approximately 4:30 p.m. PT on Tuesday, July 26, 2016 through 5:00 p.m. PT on Friday, July 29, 2016 by calling 888-203-1112 (domestic) or 719-457-0820 (international); conference ID 2574870
• Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences